Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioage LabsHAM:Y7G -7.55%20 Return-on-Tangible-Equity is -27.74% as of Jun. 2026. GuruFocus rates HAM:Y7G with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 895 Drug Manufacturers companies, Bioage Labs ranks worse than 87.71% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bioage Labs's annualized net income for the quarter that ended in Jun. 2026 was €-90.61 Mil. Bioage Labs's average shareholder tangible equity for the quarter that ended in Jun. 2026 was €326.68 Mil. Therefore, Bioage Labs's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was -27.74%.
The historical rank and industry rank for Bioage Labs's Return-on-Tangible-Equity or its related term are showing as below:
HAM:Y7G'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -94.98 Med: -61.04 Max: -27.09
Current: -29.55
During the past 4 years, Bioage Labs's highest Return-on-Tangible-Equity was -27.09%. The lowest was -94.98%. And the median was -61.04%.
HAM:Y7G's Return-on-Tangible-Equity is ranked worse than 87.71% of 895
companies
in the Drug Manufacturers industry
Industry Median: 7.61
vs HAM:Y7G: -29.55
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bioage Labs Return-on-Tangible-Equity Related Terms
Bioage Labs Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bioage Labs's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:Y7G vs PCRX, ALVO, AMPH: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioage Labs Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bioage Labs's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -27.74% mean?
Bioage Labs (HAM:Y7G) has a Return-on-Tangible-Equity of -27.74% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bioage Labs and its competitors. According to the industry distribution chart, Bioage Labs ranks #785 out of 895 companies in the Drug Manufacturers industry, placing it in the top 87.7%.
Is Bioage Labs' Return-on-Tangible-Equity too high?
Bioage Labs' current Return-on-Tangible-Equity is -27.74%. Based on the distribution chart, Bioage Labs ranks #785 out of 895 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bioage Labs has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Bioage Labs' Return-on-Tangible-Equity compare to PCRX and ALVO?
According to the Drug Manufacturers industry distribution chart, Bioage Labs ranks #785 out of 895 companies for Return-on-Tangible-Equity. This places Bioage Labs in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.61, based on 895 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bioage Labs and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioage Labs's current Return-on-Tangible-Equity is -27.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioage Labs stock overvalued right now?
Bioage Labs (HAM:Y7G) has a current Return-on-Tangible-Equity of -27.74%. The current Return-on-Tangible-Equity is -27.74%. Bioage Labs' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bioage Labs (HAM:Y7G), the current Return-on-Tangible-Equity is -27.74% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
20GF Score
Get the complete analysis for HAM:Y7G
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:Y7G has been successfully added to your 
